Drug Discovery World

MARCH 8, 2023

The first €7 million of this funding contributes to the development of the Phase II clinical study in Long Covid, the first results of which should be available by the end of this year.” The post €25 million to support clinical developments against Long Covid appeared first on Drug Discovery World (DDW).

Clinical Development 52

Clinical Development Development Vaccination Vaccine 52

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K. GAITHERSBURG, Md.,

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

XTalks

SEPTEMBER 5, 2023

Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals.

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

Drug Discovery World

OCTOBER 24, 2023

One of the key presentations will be given by Dr Qasim Ahmad, Chief Medical Officer of IO Biotech, a Clinical Oncologist with two decades of strategic clinical development, medical affairs, and marketing authorisation expertise. Register for free to secure your place!

Vaccination 52

Vaccination Vaccine Research Clinical Development 52

XTalks

OCTOBER 31, 2023

GlaxoSmithKline (GSK) Canada has roped in both older and younger versions of Wayne Gretzky for a new ad for its respiratory syncytial virus (RSV) vaccine Arexvy. The RSV vaccine ad has the now 62-year-old hockey legend looking into a mirror and seeing his younger self, specifically an AI-generated 20-year-old version of himself.

Vaccination 97

Vaccination Vaccine FDA Approval Development 97

Drug Discovery World

OCTOBER 14, 2022

Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. The post Merck and Moderna to develop a personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccination 97

Vaccination Vaccine Development Clinical Development 97

XTalks

MAY 5, 2023

This week, the US Food and Drug Administration (FDA) approved the world’s first respiratory syncytial virus (RSV) vaccine. The shot, named Arexvy, is approved for adults aged 60 years and older and was developed by GlaxoSmithKline (GSK). Who Should Get the RSV Vaccine Arexvy?

Vaccination 105

Vaccination Vaccine FDA Approval Development 105

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Regulation 52

Regulation Vaccination Vaccine Trials 52

Drug Discovery World

JANUARY 11, 2024

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. You can also find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts.

Development 52

Development Drugs Genome Genomics 52

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

Pharmaceutical Technology

JULY 1, 2022

Pfizer has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for Paxlovid (nirmatrelvir tablets and ritonavir tablets) to treat Covid-19 patients at increased disease progression risk. An inhibitor of SARS-CoV-2 main protease (Mpro), Paxlovid is intended to be given orally.

HR 264

HR Clinical Development Trials Vaccination 264

XTalks

NOVEMBER 15, 2023

France-based biotech Valneva has won approval from the US Food and Drug Administration (FDA) for its chikungunya vaccine Ixchiq for the prevention of infection from the chikungunya virus. The vaccine is approved for adults 18 years of age and older who are at increased risk of exposure to the virus.

FDA Approval 59

FDA Approval Vaccination Vaccine In-Vitro 59

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Innovative new vaccines are being created more rapidly than ever before.

Vaccination 87

Vaccination Vaccine Development Marketing 87

XTalks

NOVEMBER 4, 2022

Pfizer announced positive top-line data from a Phase III trial evaluating its respiratory syncytial virus (RSV) prefusion vaccine candidate, RSVpreF (or PF-06928316) for pregnant individuals to help protect their infants from RSV disease after birth. Related: Pfizer to Acquire RSV Antiviral Developer ReViral in $525 Million Deal.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

pharmaphorum

AUGUST 11, 2020

Russia has become the first country in the world to approve a coronavirus vaccine, amid scepticism from international experts who have been unable to review or verify clinical data from the jab called ‘Sputnik V’ According to press reports the vaccine has been tested on one of President Vladimir Putin’s daughters.

Vaccination 98

Vaccination Vaccine Trials Clinical Development 98

Pharmaceutical Technology

MARCH 1, 2023

The Covid-19 pandemic led to massive developments and scientific advances within the field of messenger ribonucleic acid (mRNA) vaccines. Pfizer /BioNTech and Moderna’s mRNA-based vaccines were the first to receive emergency use authorisation (EUA) out of all other Covid-19 vaccines under development in late 2020.

RNA 147

RNA Vaccination Vaccine Genetics 147

XTalks

MARCH 1, 2021

(NYSE: PFE ) and BioNTech SE (Nasdaq: BNTX ) have announced that they are beginning a trial to evaluate the safety and efficacy of a third booster dose for their COVID-19 vaccine (BNT162b2), as well as new vaccine variants. Related: Could Pfizer and BioNTech’s COVID-19 Vaccine be Stored at Standard Freezer Temperatures?

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

Roots Analysis

FEBRUARY 26, 2024

Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. Our Social Media Platform Web: [link] LinkedIn: [link] Twitter: [link] The post Subcutaneous Medications and Drug Delivery Systems appeared first on Blog.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . VLA15 is the only Lyme disease vaccine candidate currently in clinical development. Official comments . ” . References . 1: Valneva. April 2022.

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

VirTrial

OCTOBER 25, 2023

Vaccine studies can be large, multinational endeavors with sensitive timeframes, extended participation follow-up periods, multiphase designs, and critical data management needs. In recent years, Signant has been a part of more than 95 vaccine studies involving 140,000+ patients in more than 30 countries.

Vaccination 52

Vaccination Vaccine Development Clinical Trials 52

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

pharmaphorum

DECEMBER 7, 2020

China’s Sinovac has raised $515 million to increase its distribution and production capacity as clinical development of its potential coronavirus vaccine nears conclusion. Sinovac has a coronavirus vaccine in late-stage development, which is undergoing large-scale trials in Brazil, Pakistan, Indonesia and Chile.

Vaccination 59

Vaccination Vaccine Production Clinical Development 59

pharmaphorum

MARCH 7, 2022

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. . of individuals in low-income countries have received their first dose.

Vaccination 98

Vaccination Vaccine Manufacturing Production 98

Pharmaceutical Technology

MAY 31, 2023

GRANITE-001 is under clinical development by Gritstone Bio and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs for Adenocarcinoma Of The Gastroesophageal Junction have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III.

Clinical Trials 100

Clinical Trials Clinical Trials Vaccination Vaccine 100

XTalks

OCTOBER 4, 2023

In my current role, I have country-level responsibility for AstraZeneca’s entire portfolio, including cardiovascular, respiratory, vaccines and oncology. How is the shift toward value-based healthcare affecting drug pricing and reimbursement? And there are a couple of reasons for that.

Marketing 105

Marketing Development Drugs Gene Therapy 105

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccination 52

Vaccination Vaccine Development Immune Response 52

Pharmaceutical Technology

JANUARY 2, 2023

BI-1361849 is under clinical development by Boehringer Ingelheim International and currently in the Phase II in clinical pathway. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BI-1361849 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Drugs 100

Drugs Production Manufacturing Development 100

Drug Discovery World

FEBRUARY 10, 2023

Clinical drug trials have made the headlines this week, as it was revealed that breast cancer still tops the bill for number of clinical studies and the shortcomings in current methods to ensure representation of patient populations in trials were exposed.

Drugs 52

Drugs Clinical Trials Clinical Trials Trials 52

pharmaphorum

MARCH 22, 2021

million grant from the European Commission to accelerate clinical development of mRNA therapies for hard-to-treat cancers. mRNA therapies have been in the spotlight since BioNTech and Pfizer used the technology to create a vaccine against COVID-19 last year. Belgian immunotherapy firm eTheRNA has received a €6.9

Vaccination 62

Vaccination Vaccine Development Trials 62

Drug Discovery World

DECEMBER 22, 2022

Shelley McLendon , SVP of Vaccine and Infectious Diseases Program Management at ICON, attended the World Vaccine Congress Europe from 16-19 October 2022 in Barcelona, Spain. Additionally, to fully take advantage of the opportunity that surveillance provides for vaccine efficacy trials, institutional trust must be restored.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JUNE 5, 2023

Kid EDV is under clinical development by ImmunityBio and currently in Phase I for Pediatric Diffuse Intrinsic Pontine Glioma. According to GlobalData, Phase I drugs for Pediatric Diffuse Intrinsic Pontine Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Immune Response 130

Immune Response Clinical Trials Clinical Trials Development 130

Pharmaceutical Technology

JUNE 6, 2023

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

RNA 100

RNA Protein Antibody Vaccination 100

Pharmaceutical Technology

NOVEMBER 21, 2022

Under the partnership, the parties will establish a joint laboratory at the Bioprocessing Technology Institute (BTI) of A*STAR for developing a preclinical manufacturing platform. RVAC is currently developing mRNA-based vaccines against infectious diseases such as Covid-19.

Manufacturing 130

Manufacturing Medicine Vaccination Vaccine 130

pharmaphorum

FEBRUARY 10, 2022

AstraZeneca confirmed today that it has discontinued clinical development of a follow-up to its COVID-19 vaccine Vaxzevria targeted at the Beta variant of the virus, which started development before the emergence of the Delta and Omicron strains.

Vaccination 52

Vaccination Vaccine Development Immune Response 52

Pharmaceutical Technology

FEBRUARY 24, 2023

ACE-1334 is under clinical development by Merck and currently in Phase I for Lung Disease. According to GlobalData, Phase I drugs for Lung Disease have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Production 100

Production Vaccination Vaccine Engineer 100

Pfizer

JULY 19, 2022

1 Adapted Bivalent Vaccine Candidate. 1 Adapted Bivalent Vaccine Candidate. NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 Tue, 07/19/2022 - 11:22. Booster Series.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

Delveinsight

JULY 27, 2021

Various Active Pharmaceuticals & Biotechnological Companies including Cassava Sciences, INmune Bio, Cognito Therapeutics, Cortexyme among others presented their new and upcoming drugs, therapies, shared their research studies and clinical data. An Awaited Ulcerative Colitis Phase 2 Seres Therapeutics Trial Drug Crashed Down.

Vaccination 96

Vaccination Vaccine Trials Manufacturing 96